Archimica

Sandycroft, United Kingdom Founded: 1999 • Age: 27 yrs Acquired By PI Health Sciences
Develops nucleic acid analysis tools for research and clinical diagnostics applications
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 2 Known backers
Products 3 Services tracked
Competitors 10 Brand Intelligence

About Archimica

Archimica is a company based in Sandycroft (United Kingdom) founded in 1999 was acquired by PI Health Sciences in April 2023. Archimica offers products and services including Cytarabine, Hydroxyurea, and Mianserin. Archimica operates in a competitive market with competitors including Neogen, Parse Biosciences, Qiagen, Biofidelity and Fluent BioSciences, among others.

  • Headquarter Sandycroft, United Kingdom
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Archimica S.P.A.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
    Euticals

    & 1 more

  • Employee Count
    Employee Count
  • Acquired by
    PI Health Sciences

    & 1 more

    (Apr 28, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Archimica

Archimica offers a comprehensive portfolio of products and services, including Cytarabine, Hydroxyurea, and Mianserin.

Primary

Nucleoside analogue for cancer treatment applications

Modified urea used in medical therapies

Tetracyclic compound for pharmaceutical purposes

Funding Insights of Archimica

Investors in Archimica

Archimica has secured backing from 2 investors. Prominent investors backing the company include Euticals and PI Health Sciences.

All
Investor Description Founded Year Domain Location
Specializes in CRO and CDMO services for medicinal chemistry and API manufacturing.
Founded Year Domain Location
APIs, custom synthesis, and fine chemicals are developed and manufactured.
Founded Year Domain Location

Investments & Acquisitions by Archimica

Investments

Financial Statements - Archimica

Archimica Comparisons

+
Add Comparison
Available on Premium

Competitors of Archimica

Archimica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neogen, Parse Biosciences, Qiagen, Biofidelity and Fluent BioSciences, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
domain founded_year HQ Location
RNA-sequencing transcriptome kits for health data analysis are developed.
domain founded_year HQ Location
Products and reagents for molecular diagnostic assays are supplied.
domain founded_year HQ Location
Molecular diagnostic assays are developed for target DNA sequence detection.
domain founded_year HQ Location
Proprietary reagents for single-cell genetic analysis are developed.
domain founded_year HQ Location
Digital PCR solutions for research are developed and analyzed.

Latest news on Archimica

Frequently Asked Questions about Archimica

Archimica was founded in 1999.

Archimica is headquartered in Sandycroft, United Kingdom.

Norbert Dieterich is the current CEO of Archimica.

Archimica was established in 1999 in Sandycroft, United Kingdom, within the biotechnology sector focused on molecular diagnostics. Nucleic acid analysis tools are created for research and clinical use, including next-generation real-time polymerase chain reaction systems. Operations center on advancing diagnostic technologies, with the company accessible via archimica.com. Leadership is provided by CEO Norbert Dieterich, supporting applications in healthcare and scientific research.

Archimica's top competitors include Neogen, Stilla Technologies and Qiagen.

Archimica offers Cytarabine, Hydroxyurea, and Mianserin.

Archimica has 2 investors. Key investors include Euticals, and PI Health Sciences.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available